Tissue Acquisition, Processing, and Pathology (TAPP) Core
Tissue Acquisition, Processing, and Pathology (TAPP) Core
批准号:
8677704
负责人:
MICHAEL D KALOS
金额:
$12.65万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AnatomyAntigensArchivesBiological AssayBiological MarkersCell LineCessation of lifeChestClinicalClinical TrialsDiagnosisEnrollmentGoalsIceInstructionInterferon-alphaInterferonsMalignant NeoplasmsNeoplasm AntibodiesOperative Surgical ProceduresPathologicPathologistPathologyPathology processesPatientsProcessRoleSamplingSerologicalSerumSpecimenSpecimen HandlingTissuesTumor AntigensTumor-Derivedimmuno-gene therapymesothelinneutralizing antibodystable cell linetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY (See instructions):
The Goals of the Tissue Acquisition, Prcoessing and Pathology Core are:
A. Review and analyze pathologic specimens from clinical trial patients (with Project 1), including expression of mesothelin levels and potentially other tumor antigens.
B. Process and archive clinical specimens from ongoing and planned clinical trials (with Project 1).
C Perform assays for Interferon-alpha, anti-adenoviral neutralizing antibodies, serum mesothelin, and antitumor antibodies (with Project 1)
D. Tissue acquisition (with Projects 1, 2 and 3).
E. Establish stable cell lines from tumors derived from clinical trial subjects and other surgical patients (with Projects 1, 2, and 3).
F. Assist in immunohistochemical analyses
Dr. Michael Kalos will be the Director of the TAPP Core due to the unfortunate death of Dr. Carroll. Dr. Leslie Litzky, a Board-Certified Anatomic Pathologist, will focus on goal A and continue in her previous role as the designated reference pathologist for confirmation of diagnosis prior to patient enrollment in clinical trials and review of mesothelin or other antigen expression on tumor samples. Dr. Steven Albelda who has
the expertise needed to perform revised Goals C (previously established serological assays) and E (cell line establishment) will assist in this core.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
-
批准号:8396738
-
项目类别:
-
资助金额:$33.86万
-
财政年份:2012
-
负责人:MICHAEL D KALOS
-
依托单位:
ACQUISITION OF PERIPHERAL BLOOD AND BONE MARROW TO SUPPORT LABORATORY CORRELA
-
批准号:7982069
-
项目类别:
-
资助金额:$0.35万
-
财政年份:2008
-
负责人:MICHAEL D KALOS
-
依托单位:
ACQUISITION OF PERIPHERAL BLOOD AND BONE MARROW TO SUPPORT LABORATORY CORRELA
-
批准号:7716655
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2008
-
负责人:MICHAEL D KALOS
-
依托单位:
ACQUISITION OF PERIPHERAL BLOOD AND BONE MARROW TO SUPPORT LABORATORY CORRELA
-
批准号:7603884
-
项目类别:
-
资助金额:$1.84万
-
财政年份:2006
-
负责人:MICHAEL D KALOS
-
依托单位:
ACQUISITION OF PERIPHERAL BLOOD AND BONE MARROW TO SUPPORT LABORATORY
-
批准号:7368183
-
项目类别:
-
资助金额:$0.33万
-
财政年份:2005
-
负责人:MICHAEL D KALOS
-
依托单位:
Tissue Acquisition, Processing, and Pathology (TAPP) Core
-
批准号:8291483
-
项目类别:
-
资助金额:$13.24万
-
财政年份:1997
-
负责人:MICHAEL D KALOS
-
依托单位:
COMPREHENSIVE GENETIC ANALYSIS OF TAT EXTINCTION
-
批准号:2169099
-
项目类别:
-
资助金额:$1.5万
-
财政年份:1993
-
负责人:MICHAEL D KALOS
-
依托单位:
COMPREHENSIVE GENETIC ANALYSIS OF TAT EXTINCTION
-
批准号:3046071
-
项目类别:
-
资助金额:$2.86万
-
财政年份:1992
-
负责人:MICHAEL D KALOS
-
依托单位:
COMPREHENSIVE GENETIC ANALYSIS OF TAT EXTINCTION
-
批准号:3046070
-
项目类别:
-
资助金额:$2.27万
-
财政年份:1992
-
负责人:MICHAEL D KALOS
-
依托单位:
Tissue Acquisition, Processing, and Pathology (TAPP) Core
-
批准号:8566678
-
项目类别:
-
资助金额:$12.06万
-
财政年份:--
-
负责人:MICHAEL D KALOS
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: